Skip to main content

Table 2 Cox regression analysis of death and reoperation

From: Long-term survival after Carpentier-Edwards Perimount aortic valve replacement in Western Denmark: a multi-centre observational study

  Death Reoperation
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Male gender 1.07 (0.92–1.24) 0.360 1.56 (0.91–2.66) 0.107
Age groupa
 65–70 1.0   1.0  
  < 50 1.35 (0.55–3.33) 0.516 5.61 (1.59–19.8) 0.007*
 50–65 1.05 (0.74–1.51) 0.77 2.44 (1.17–5.08) 0.017*
 70–80 1.81 (1.43–2.28) < 0.001* 0.71 (0.37–1.38) 0.312
  ≥ 80 3.19 (2.46–4.12) < 0.001* 0.60 (0.21–1.70) 0.337
Reoperationb 1.06 (0.74–1.52) 0.747   
Valve size
 25 1.0   1.0  
 19–23 1.22 (1.03–1.45) 0.025* 0.73 (0.42–1.26) 0.252
 27–29 0.94 (0.71–1.25) 0.658 1.03 (0.45–2.34) 0.948
Diabetes Mellitus 1.22 (0.99–1.51) 0.067* 1.38 (0.68–2.81) 0.369
Smoker 1.59 (1.29–1.97) < 0.001* 1.61 (0.74–3.52) 0.234
Previous smoker 1.08 (0.91–1.28) 0.383 1.39 (0.77–2.51) 0.269
VP-PM 1.18 (0.95–1.48) 0.144 2.19 (1.21–3.98) 0.010*
EuroSCORE II < 4% 0.61 (0.43–0.87) 0.006* 0.12 (0.06–0.22) < 0.001*
Hypertension treatment 1.01 (0.87–1.17) 0.889 0.98 (0.59–1.64) 0.945
Lipid-lowering treatmentc 0.68 (0.58–0.80) < 0.001* 1.09 (0.61–1.96) 0.759
  1. VP-PM Valve prosthesis-patient mismatch. *P < 0.05
  2. aAge groups for reoperation are sorted by the age of the primary CE-P procedure
  3. bReoperation after primary AVR with another CE-P or TAVR
  4. cCox regression of the first 10 years